Tags

Type your tag names separated by a space and hit enter

p53 as a marker of prognosis in African-American women with breast cancer.
Ann Surg Oncol. 2010 May; 17(5):1398-405.AS

Abstract

BACKGROUND

p53 overexpression has been identified as a poor prognostic marker in breast cancer. We investigate the value of p53 status within the context of stage and intrinsic subtype classification (subtype), in a group of African-American (AA) women of lower socioeconomic status (SES) with primary breast cancer.

METHODS

Participants were 331 consecutive AA women treated at an urban hospital (median follow-up 41 months) with known subtype [luminal A = estrogen receptor (ER)+ and/or progesterone receptor (PR)+, human epidermal growth factor receptor 2 (HER2)-; luminal B = ER+ and/or PR+, HER2+; HER2+ = ER-, PR-, HER2+; basal = ER-, PR-, HER2-, cytokeratin (CK)5/6+, and/or HER1+; and unclassified = negative for all five markers] and p53 (Pab1801 antibody) immunohistochemical status. Proportional hazards regression models were used to select and evaluate factors prognostic for all-cause mortality.

RESULTS

p53+ status was associated with grade 3 tumors, ER/PR- status, and basal subtype. On univariate analysis, factors related to survival were stage, grade [(3/1) hazard ratio (HR) = 2.64; 95% confidence interval (CI), 1.15-6.07], subtype [(ex. basal/luminal A) HR = 2.15; 95% CI, 1.34-3.45], and p53 status [(+/-) HR = 1.77; 95% CI, 1.15-2.72]. Multivariable modeling indicated that p53+ status remained a negative prognostic factor (HR = 1.63; 95% CI, 1.01-2.59) after adjustment for effects of age, stage, grade, and subtype; 5-year adjusted survival was significantly greater for p53- (66.7%) than p53+ cases (54.7%).

CONCLUSION

p53 status is an independent predictor of survival after consideration of other strong prognostic factors such as stage, tumor grade, and subtype, and thus may be useful in identifying AA women at high risk of breast cancer mortality.

Authors+Show Affiliations

The Cancer Foundation for Minority and Underserved Populations, Chicago, IL, USA. keithdookeran@chicagobooth.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20049641

Citation

Dookeran, Keith A., et al. "P53 as a Marker of Prognosis in African-American Women With Breast Cancer." Annals of Surgical Oncology, vol. 17, no. 5, 2010, pp. 1398-405.
Dookeran KA, Dignam JJ, Ferrer K, et al. P53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol. 2010;17(5):1398-405.
Dookeran, K. A., Dignam, J. J., Ferrer, K., Sekosan, M., McCaskill-Stevens, W., & Gehlert, S. (2010). P53 as a marker of prognosis in African-American women with breast cancer. Annals of Surgical Oncology, 17(5), 1398-405. https://doi.org/10.1245/s10434-009-0889-3
Dookeran KA, et al. P53 as a Marker of Prognosis in African-American Women With Breast Cancer. Ann Surg Oncol. 2010;17(5):1398-405. PubMed PMID: 20049641.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - p53 as a marker of prognosis in African-American women with breast cancer. AU - Dookeran,Keith A, AU - Dignam,James J, AU - Ferrer,Karen, AU - Sekosan,Marin, AU - McCaskill-Stevens,Worta, AU - Gehlert,Sarah, Y1 - 2010/01/05/ PY - 2009/09/21/received PY - 2010/1/6/entrez PY - 2010/1/6/pubmed PY - 2010/7/30/medline SP - 1398 EP - 405 JF - Annals of surgical oncology JO - Ann Surg Oncol VL - 17 IS - 5 N2 - BACKGROUND: p53 overexpression has been identified as a poor prognostic marker in breast cancer. We investigate the value of p53 status within the context of stage and intrinsic subtype classification (subtype), in a group of African-American (AA) women of lower socioeconomic status (SES) with primary breast cancer. METHODS: Participants were 331 consecutive AA women treated at an urban hospital (median follow-up 41 months) with known subtype [luminal A = estrogen receptor (ER)+ and/or progesterone receptor (PR)+, human epidermal growth factor receptor 2 (HER2)-; luminal B = ER+ and/or PR+, HER2+; HER2+ = ER-, PR-, HER2+; basal = ER-, PR-, HER2-, cytokeratin (CK)5/6+, and/or HER1+; and unclassified = negative for all five markers] and p53 (Pab1801 antibody) immunohistochemical status. Proportional hazards regression models were used to select and evaluate factors prognostic for all-cause mortality. RESULTS: p53+ status was associated with grade 3 tumors, ER/PR- status, and basal subtype. On univariate analysis, factors related to survival were stage, grade [(3/1) hazard ratio (HR) = 2.64; 95% confidence interval (CI), 1.15-6.07], subtype [(ex. basal/luminal A) HR = 2.15; 95% CI, 1.34-3.45], and p53 status [(+/-) HR = 1.77; 95% CI, 1.15-2.72]. Multivariable modeling indicated that p53+ status remained a negative prognostic factor (HR = 1.63; 95% CI, 1.01-2.59) after adjustment for effects of age, stage, grade, and subtype; 5-year adjusted survival was significantly greater for p53- (66.7%) than p53+ cases (54.7%). CONCLUSION: p53 status is an independent predictor of survival after consideration of other strong prognostic factors such as stage, tumor grade, and subtype, and thus may be useful in identifying AA women at high risk of breast cancer mortality. SN - 1534-4681 UR - https://www.unboundmedicine.com/medline/citation/20049641/p53_as_a_marker_of_prognosis_in_African_American_women_with_breast_cancer_ L2 - https://dx.doi.org/10.1245/s10434-009-0889-3 DB - PRIME DP - Unbound Medicine ER -